Pune, India, August 2019, MRFR Press Release/- Market Research Future has Published a Cooked Research Report on the Global Osteosarcoma Market
Osteosarcoma is a disease afflicting the bone, where there is a proliferation of osteoblasts. It is one of the most common type of cancer where immature bones are formed and is mostly common in children and teenagers. Market Research Future (MRFR) has launched a report on the global osteosarcoma market that is a compilation of all the pertinent trends and patterns that could affect the market over the forecast period of 2017-2023. MRFR has predicted a CAR of 6.40% over the forecast period.
The occurrence of osteosarcoma is soaring among children and is more dominant among males. Osteosarcoma is accountable for almost 2% of childhood cancers and its occurrence is very rare in adults. Rise in pediatric population is supporting the growth of the osteosarcoma market. Various therapies aimed at treating the disease are available in the market Such methods include chemotherapy, cisplatin, high-dose methotrexate with leucovorin. Aggressive R&D activities and clinical trials are underway to come up with new treatments and therapies which is likely to augment the growth of the market in the coming years.
On the other hand, high cost of treatment and unavailability of alternative treatment options are hindrances to the growth of the osteosarcoma market.
The osteosarcoma market has been segmented based on type, diagnosis, treatment, and end user.
By type, the osteosarcoma market has been segmented into intramedullary osteosarcoma, juxtacortical osteosarcoma, and extra-skeletal osteosarcoma.
By diagnosis, the osteosarcoma market has been segmented into biopsy, X-ray, MRI, CT Scan, bone scan, and others.
By treatment, the osteosarcoma market has been segmented into chemotherapy, surgery, radiation therapy, and others.
By end user, the osteosarcoma market has been segmented into hospitals & clinics, cancer research centers, and others.
Access Report Details @ https://www.marketresearchfuture.com/reports/osteosarcoma-market-4412
Region-wise, the osteosarcoma market has been segmented into the Americas, the Middle East & Africa (MEA), Europe, and Asia Pacific (APAC).
The Americas is leading the global osteosarcoma market on account of expanding population base of patients suffering from the disease, and elevating level of support from the government for R&D of new treatment options. The prevalence of the disease is increasing among children which has resulted in high diagnosis rate. The availability of advanced diagnosis and treatment options and a robust healthcare system also underpins the growth of the market. Various market players based in the region are also involved in aggressive R&D activities which further supports the growth of the market.
Europe has secured the second spot in the global osteosarcoma market. Intense R&D activities aimed at the development of new treatment options and surging awareness regarding the disease is supporting the growth of the market. Prolific growth of the medical device industry can also be credited for the growth of the market. The UK, France, and Germany are the key contributors to the Europe market.
The APAC osteosarcoma market is likely to exhibit the highest CAGR over the forecast period. Surging prevalence of the disease along with the rising awareness is fueling the market growth. Increasing availability of advanced treatment facilities and government support are other driving factors.
Low availability of medical facilities and limited progress of the healthcare sector in the MEA region is responsible for the subdued growth of the MEA osteosarcoma market. Growth within the market is mainly driven by the Gulf countries who are endeavoring to upgrade their healthcare facilities.
Pfizer (U.S.), Baxter (U.S.), Hikma Pharmaceuticals (U.K), Novartis (U.S.), Spectrum Pharmaceuticals, Inc. (U.S.), Advaxis Inc., Bellicum Pharmaceuticals (U.S.), and Inc. Isofol Medical AB (Sweden) are the notable players in the osteosarcoma market.